Steven J Swanson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10909673/publications.pdf

Version: 2024-02-01

46 papers

2,705 citations

236925 25 h-index 243625 44 g-index

47 all docs

47 docs citations

times ranked

47

1457 citing authors

#	Article	IF	CITATIONS
1	Clinical Manifestations of an Anti-Drug Antibody Response: Autoimmune Reactions. Journal of Interferon and Cytokine Research, 2014, 34, 953-957.	1.2	O
2	Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis, 2014, 6, 1509-1523.	1.5	27
3	Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics. AAPS Journal, 2013, 15, 30-40.	4.4	37
4	Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. Journal of Immunological Methods, 2013, 396, 44-55.	1.4	34
5	Immunogenicity testing strategy and bioanalytical assays for antibody–drug conjugates. Bioanalysis, 2013, 5, 1041-1055.	1.5	33
6	Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrology Dialysis Transplantation, 2012, 27, 688-693.	0.7	22
7	Immunogenicity assessment in non-clinical studies. Current Opinion in Microbiology, 2012, 15, 337-347.	5.1	34
8	Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. Journal of Immunological Methods, 2012, 382, 93-100.	1.4	19
9	Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing. Journal of Immunological Methods, 2012, 382, 129-141.	1.4	18
10	Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1265-1274.	2.8	18
11	Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clinical Pharmacology, 2011, 11, 17.	2.5	23
12	Comparing Exponentially Weighted Moving Average and Run Rules in Process Control of Semiquantitative Immunogenicity Immunoassays. AAPS Journal, 2010, 12, 79-86.	4.4	8
13	Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Annals of Hematology, 2010, 89, 75-85.	1.8	28
14	Identification and inhibition of drug target interference in immunogenicity assays. Journal of Immunological Methods, 2010, 355, 21-28.	1.4	57
15	Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. Journal of Immunological Methods, 2010, 357, 10-16.	1.4	57
16	Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis, 2010, 2, 721-731.	1. 5	16
17	Immunogenicity of Therapeutic Proteins. , 2010, , 105-117.		O
18	Assessing specificity for immunogenicity assays. Bioanalysis, 2009, 1, 611-617.	1.5	15

#	Article	IF	Citations
19	The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 415-426.	2.8	41
20	A Step-wise Approach for Transfer of Immunogenicity Assays during Clinical Drug Development. AAPS Journal, 2009, 11, 526-34.	4.4	6
21	Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. Journal of Immunological Methods, 2008, 333, 1-9.	1.4	326
22	Feasibility of a Multiplex Flow Cytometric Bead Immunoassay for Detection of Anti-Epoetin Alfa Antibodies. Vaccine Journal, 2007, 14, 1165-1172.	3.1	13
23	Immunogenicity Issues in the Development of Therapeutic Proteins. Pharmaceutical Medicine, 2007, 21, 207-216.	0.4	5
24	Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab. Journal of Immunology, 2007, 178, 7467-7472.	0.8	181
25	A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum. Journal of Pharmaceutical and Biomedical Analysis, 2007, 45, 583-589.	2.8	5
26	Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. Journal of Immunological Methods, 2007, 321, 1-18.	1.4	225
27	Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson's Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion. Journal of Clinical Immunology, 2007, 27, 620-627.	3.8	64
28	Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. Journal of Immunological Methods, 2006, 308, 101-108.	1.4	78
29	A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. Journal of Immunological Methods, 2006, 316, 8-17.	1.4	11
30	Immunogenicity Issues in Drug Development. Journal of Immunotoxicology, 2006, 3, 165-172.	1.7	15
31	An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. Journal of Immunological Methods, 2005, 304, 189-195.	1.4	178
32	Immunogenicity Testing by Electrochemiluminescent Detection for Antibodies Directed against Therapeutic Human Monoclonal Antibodies. Clinical Chemistry, 2005, 51, 1983-1985.	3.2	74
33	Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins. Vaccine Journal, 2005, 12, 28-39.	3.1	42
34	Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrology Dialysis Transplantation, 2005, 20, iv16-iv22.	0.7	37
35	Evaluation of Methods to Detect and Characterize Antibodies against Recombinant Human Erythropoietin. Nephron Clinical Practice, 2004, 96, c88-c95.	2.3	85
36	Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of Immunological Methods, 2004, 289, 1-16.	1.4	576

#	Article	IF	CITATIONS
37	Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. Journal of Immunological Methods, 2004, 293, 115-126.	1.4	39
38	Drug-induced and antibody-mediated pure red cell aplasia: A review of literature and current knowledge. Biotechnology Annual Review, 2004, 10, 237-250.	2.1	29
39	Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Current Medical Research and Opinion, 2003, 19, 651-659.	1.9	54
40	Detection and Characterization of Antibodies to PEG-IFN-alpha2b Using Surface Plasmon Resonance. Journal of Interferon and Cytokine Research, 1999, 19, 781-789.	1.2	27
41	Validation parameters for a novel biosensor assay which simultaneously measures serum concentrations of a humanized monoclonal antibody and detects induced antibodies. Journal of Immunological Methods, 1997, 209, 1-15.	1.4	57
42	Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP). BBA - Proteins and Proteomics, 1992, 1160, 309-316.	2.1	15
43	Binding and immunological properties of a synthetic peptide corresponding to the phosphorylcholine-binding region of C-reactive protein. Molecular Immunology, 1990, 27, 679-687.	2.2	21
44	Characteristics of the binding of human C-reactive protein (CRP) to laminin. Journal of Cellular Biochemistry, 1989, 40, 121-132.	2.6	26
45	Pore diffusion in packed-bed reactors containing immobilized glucoamylase. AICHE Journal, 1978, 24, 30-34.	3.6	13
46	Kinetics of maltose hydrolysis by glucoamylase. Biotechnology and Bioengineering, 1977, 19, 1715-1718.	3.3	15